

## Julian Adams

Julian Adams, Ph.D., serves as chief executive officer of Gamida Cell (NASDAQ:GMDA), a clinical-stage biopharmaceutical company working to develop cell therapies for cancer and rare, serious hematologic diseases. Dr. Adams joined Gamida Cell's in November 2017, bringing more than 35 years of drug discovery and development experience to his role. He has served on the board since September 2016. Prior to his CEO appointment, Dr. Adams served as the president of research and development at Infinity Pharmaceuticals, Inc., where he built and led the company's R&D efforts, which resulted in numerous IND filings and development of small molecule drugs to treat cancer. Of note, he was instrumental at developing an oral inhibitor of phosphoinositide 3-kinase (PI3K), also known as duvelisib. In 2018, the FDA approved COPIKTRA (duvelisib, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Prior to Infinity Dr. Adams served as the senior vice president, drug discovery and development at Millennium Pharmaceuticals, now part of Takeda Oncology. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer and multiple myeloma. Earlier in his career, he was credited with discovering Viramune® (nevirapine) for HIV at Boehringer Ingelheim. Dr. Adams has also held senior leadership roles in research and development at LeukoSite, Inc. and ProScript.

Dr. Adams has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. Dr. Adams is an inventor of more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals. He is the editor of *Proteasome Inhibition in Cancer Therapy*, published in July 2004.

Dr. Adams currently serves as executive chairman at Elicio Therapeutics, and he is also a scientific advisor and program reviewer for Stand Up To Cancer.

Dr. Adams received his B.S. from McGill University in 1977 and his Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry in 1981. He also received the degree of Doctor of Science, honoris causa, from McGill University in 2012.